Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by intense itching, dry skin, and recurrent flares. Effective management requires a multifaceted approach tailored to disease severity, patient age, and lesion distribution. Treatment strategies emphasize restoring the skin barrier, reducing inflammation, relieving pruritus, and preventing exacerbations through basic care, topical therapies, systemic interventions, and patient education.
What is the treatment for atopic dermatitis?
The primary goals of treatment are to alleviate symptoms, improve quality of life, minimize flares, and enable normal daily activities. Therapy is individualized based on mild, moderate, or severe disease. Basic measures form the foundation, with escalation to topical corticosteroids (TCS), calcineurin inhibitors (TCI), phototherapy, or systemic agents as needed. Recent advancements include biologics targeting IL-4/IL-13 pathways, offering hope for refractory cases.
Who treats atopic dermatitis?
Primary care physicians, pediatricians, dermatologists, and allergists manage atopic dermatitis. For mild cases, general practitioners suffice, but moderate-to-severe disease often requires specialist referral. Multidisciplinary input from psychologists for itch-scratch cycles or dietitians for food triggers enhances outcomes.
Basic skin care for atopic dermatitis
Daily skin hydration is cornerstone therapy. Emollients should be applied generously 2-3 times daily, especially after bathing, to repair the defective skin barrier and reduce transepidermal water loss. Choose fragrance-free, preservative-free ointments or creams matching patient preference. Bathing with lukewarm water using gentle, soap-free cleansers for 5-10 minutes followed by immediate emollient application prevents dryness without stripping natural oils.
- Emollients: Petrolatum-based ointments for severe dryness; lighter creams for humid climates.
- Bathing: Avoid hot water, harsh soaps; dilute bleach baths (0.5 cup in full tub) 2-3 times weekly reduce bacterial colonization in infected flares.
- Clothing: Cotton fabrics; avoid wool, synthetics that irritate.
Avoidance of aggravating factors
Identifying and eliminating triggers is essential. Common irritants include harsh soaps, wool clothing, excessive sweating, stress, and allergens like dust mites or foods (in infants). Maintain cool, humid environments; use hypoallergenic products. For dust mite allergy, encase mattresses in allergen-proof covers and wash bedding weekly in hot water.
- Irritants: Detergents, fragrances, rubber accelerators in gloves.
- Allergens: House dust mites, pet dander, pollen; consider allergy testing.
- Infections: Treat Staphylococcus aureus colonization with antiseptics.
- Foods: Cow’s milk, eggs in young children; supervised elimination diets if IgE-mediated.
Patient education and psychological support
Empowering patients with knowledge reduces flare frequency. Teach the itch-scratch cycle, proper emollient use, and trigger avoidance. Psychological support addresses anxiety, depression from chronic symptoms. Habit reversal therapy or cognitive behavioral techniques break scratching habits. Support groups foster coping strategies.
Topical treatment for atopic dermatitis
Topical therapies target inflammation during flares. TCS are first-line, selected by potency, site, and duration. Low-potency for face/eyelids/intertriginous areas; medium-to-high for trunk/limbs. Apply thinly once/twice daily for 7-14 days until control, then taper. Proactive therapy: intermittent low-potency TCS/TCI twice weekly prevents relapses.
| Potency | Examples | Suitable Sites | Duration |
|---|---|---|---|
| Mild | Hydrocortisone 1% | Face, flexures | Up to 4 weeks |
| Moderate | Triamcinolone 0.1% | Body, mild-moderate flares | 2-4 weeks |
| Potent | Mometasone 0.1% | Limbs, thick plaques | 1-2 weeks |
TCI (tacrolimus, pimecrolimus) steroid-sparing for sensitive sites, long-term use. Crisaborole (PDE4 inhibitor) for mild-moderate disease in children 62 years.
Wet wrap technique
For severe flares, wet wraps enhance penetration. Apply emollient/TCS to affected areas, cover with damp gauze/cloth, then dry layer. Leave 4-12 hours, typically overnight. Effective for rapid control, especially in children; hospital-supervised initially. Risks: folliculitis, maceration if too wet.
- Soak skin 15-20 min warm water.
- Pat dry, apply TCS/emollient.
- Apply wet layer (damp Tubifast).
- Occlude with dry layer.
- Monitor 1-3 days.
Antipruritic treatment
Itch control breaks the cycle. Sedating antihistamines (hydroxyzine, doxepin) at night; non-sedating (cetirizine) daytime. Gabapentin/pregabalin for neuropathic itch. Menthol 0.5-1% creams provide cooling. Address xerosis aggressively.
Treatment of infected atopic dermatitis
Secondary bacterial (Staph aureus), viral (herpes), or fungal infections complicate 90% flares. Signs: crusting, pustules, fever. Topical antiseptics (chlorhexidine), mupirocin for localized; oral cephalexin/flucloxacillin for widespread. Aciclovir for eczema herpeticum. Dilute bleach baths prevent recurrence.
Phototherapy for atopic dermatitis
Narrowband UVB (NB-UVB) second-line for moderate-severe unresponsive to topicals. 3-5 sessions/week, 4-12 weeks. Improves 70-80%; contraindicated in photosensitivity, skin type I. Home UVB emerging. UVA1 for acute flares.
Systemic treatment for atopic dermatitis
For severe, widespread disease: short-course oral prednisolone (1mg/kg, taper 2-3 weeks) for flares only—avoid chronic use due to rebound. Immunosuppressants: ciclosporin (first-line, up to 2 years), methotrexate, azathioprine, mycophenolate (off-label).
Biologics and novel therapies
IL-4/IL-13 inhibitors: dupilumab (62 months, SC every 2-4 weeks) achieves EASI-75 in 60-70% by week 16. Tralokinumab, lebrikizumab (IL-13); nemolizumab (IL-31 for pruritus). JAK inhibitors: upadacitinib, abrocitinib (oral). First-line for moderate-severe.
| Agent | Target | Age | Efficacy |
|---|---|---|---|
| Dupilumab | IL-4/IL-13 | 62 6 mo | 70% EASI-75 @52w |
| Upadacitinib | JAK1 | 62 12 y | Rapid itch relief |
| Nemolizumab | IL-31 | 62 12 y | Pruritus-focused |
Frequently Asked Questions
Q: How long does it take for topical steroids to work?
A: Improvement typically within 3-7 days; continue 7-14 days then taper to avoid rebound.
Q: Are biologics safe for children?
A: Dupilumab approved from 6 months; monitor infections, conjunctivitis.
Q: Can diet cure eczema?
A: No, but avoidance of proven IgE triggers in infants may help; not routine.
Q: What if topicals fail?
A: Escalate to phototherapy, immunosuppressants, or biologics via specialist.
Q: Is wet wrap therapy painful?
A: No, soothing; relieves itch quickly but requires correct technique.
This comprehensive approach, combining non-pharmacologic and advanced therapies, controls atopic dermatitis in most patients, with ongoing research promising further improvements.
References
- A Comprehensive Review of the Treatment of Atopic Eczema PMC. 2016-02-29. https://pmc.ncbi.nlm.nih.gov/articles/PMC4773205/
- Treatments for atopic dermatitis PMC – NIH. 2023-11-01. https://pmc.ncbi.nlm.nih.gov/articles/PMC10664093/
- Current Treatments for Atopic Dermatitis Journal of Clinical and Aesthetic Dermatology. 2024-01-01. https://jcadonline.com/current-treatments-for-atopic-dermatitis/
- Eczema (Atopic Dermatitis) Overview American Academy of Allergy, Asthma & Immunology. 2024-01-01. https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/eczema-(atopic-dermatitis)-overview
- Eczema types: Atopic dermatitis diagnosis and treatment American Academy of Dermatology. 2024-01-01. https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/treatment
- Atopic dermatitis (eczema) – Diagnosis and treatment Mayo Clinic. 2024-01-01. https://www.mayoclinic.org/diseases-conditions/atopic-dermatitis-eczema/diagnosis-treatment/drc-20353279
